open access

Vol 15, No 2 (2020)
Review Papers
Get Citation

Progress in study on natriuretic peptides

Stanisław Surma, Edward Bańkowski
Folia Cardiologica 2020;15(2):149-159.

open access

Vol 15, No 2 (2020)
Review Papers

Abstract

Natriuretic peptides (NP) are hormones mainly involved in the regulation of water and electrolyte balance and the regulation of cardiovascular function. So far, six classic NP have been described: type A natriuretic peptide, urodilatin, type B natriuretic peptide, type C natriuretic peptide, type D natriuretic peptide and uroguanylin. The family of natriuretic peptides also includes osteocrin and musculin, which have different metabolic activities. NP carry out their biological activities by interacting with three membrane receptors. The bioavailability of these compounds is regulated, among others, by neprilysin. Plasma NP concentrations change during many diseases. The most important of these include heart failure (HF). The guidelines of the European Society of Cardiology indicate that the determination of plasma peptide concentrations is helpful in the diagnosis of HF.

Understanding the physiology of natriuretic peptides has led to the search for new drugs that would mimic their beneficial effects. In addition to the beneficial effects of natriuretic peptides on the cardiovascular system, it has been shown that these compounds are involved in the regulation of many other metabolic processes — among others in the regulation of the center of hunger and satiety in the hypothalamus.

The purpose of this work is to present the definitions, history, mechanisms of natriuretic peptides, as well as their role in human physiology and pathology and to present clinical issues related to these hormones.

Abstract

Natriuretic peptides (NP) are hormones mainly involved in the regulation of water and electrolyte balance and the regulation of cardiovascular function. So far, six classic NP have been described: type A natriuretic peptide, urodilatin, type B natriuretic peptide, type C natriuretic peptide, type D natriuretic peptide and uroguanylin. The family of natriuretic peptides also includes osteocrin and musculin, which have different metabolic activities. NP carry out their biological activities by interacting with three membrane receptors. The bioavailability of these compounds is regulated, among others, by neprilysin. Plasma NP concentrations change during many diseases. The most important of these include heart failure (HF). The guidelines of the European Society of Cardiology indicate that the determination of plasma peptide concentrations is helpful in the diagnosis of HF.

Understanding the physiology of natriuretic peptides has led to the search for new drugs that would mimic their beneficial effects. In addition to the beneficial effects of natriuretic peptides on the cardiovascular system, it has been shown that these compounds are involved in the regulation of many other metabolic processes — among others in the regulation of the center of hunger and satiety in the hypothalamus.

The purpose of this work is to present the definitions, history, mechanisms of natriuretic peptides, as well as their role in human physiology and pathology and to present clinical issues related to these hormones.

Get Citation

Keywords

natriuretic peptides, cardiovascular system, heart failure, cardiovascular diseases

About this article
Title

Progress in study on natriuretic peptides

Journal

Folia Cardiologica

Issue

Vol 15, No 2 (2020)

Pages

149-159

Bibliographic record

Folia Cardiologica 2020;15(2):149-159.

Keywords

natriuretic peptides
cardiovascular system
heart failure
cardiovascular diseases

Authors

Stanisław Surma
Edward Bańkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl